Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Mengoni

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancer Gene Therapy|February 15, 2024
Transactivation of Met signaling by oncogenic Gnaq drives the evolution of melanoma in Hgf-Cdk4 miceMiriam Mengoni, Andreas Dominik Braun, Sahithi Seedarala, et al.
Frontiers in Oncology|October 21, 2022
COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchymaUlf D Kahlert, Wenjie Shi, Marco Strecker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centersNina Flatt, Corinna Kochanek, Yenny Angela, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 3, 2024
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patientsInga Hansen-Abeck, Glenn Geidel, Finn Abeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Nature|June 14, 2023
CD4<sup>+</sup> T cell-induced inflammatory cell death controls immune-evasive tumoursBastian Kruse, Anthony C Buzzai, Naveen Shridhar, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer Gene Therapy|February 15, 2024
Transactivation of Met signaling by oncogenic Gnaq drives the evolution of melanoma in Hgf-Cdk4 miceMiriam Mengoni, Andreas Dominik Braun, Sahithi Seedarala, et al.
Frontiers in Oncology|October 21, 2022
COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchymaUlf D Kahlert, Wenjie Shi, Marco Strecker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centersNina Flatt, Corinna Kochanek, Yenny Angela, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 3, 2024
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patientsInga Hansen-Abeck, Glenn Geidel, Finn Abeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Nature|June 14, 2023
CD4<sup>+</sup> T cell-induced inflammatory cell death controls immune-evasive tumoursBastian Kruse, Anthony C Buzzai, Naveen Shridhar, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 3